drugset / Trial / NCT02260063

Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers

NCT02260063

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To assess the bioequivalence of two galenic formulations for epinastine (Flurinol®): syrup and 20 mg tablets

Timeline

Start
1998-11
Primary completion
1999-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinastine Small molecule 20 mg

Indications

No indication recorded.